TA 4-SCC versus CEA sensitivity for lung cancer.
The sensitivity of a new tumor marker, TA 4-SCC, for lung tumors is examined and compared with the performance of the already established CEA. TA 4-SCC sensitivity is only moderate (30%), and it presents no significant differences among the various histologic types of lung cancer. In addition, unlike CEA, TA 4-SCC is present in large amounts in the serum of many stage I and II patients. In fact, its sensitivity in still curatively operable tumors reaches 30% compared to 10% with CEA.
Pecchio
F
F
Laboratorio Baldi e Riberi, Ospedale S. Giovanni Battista, Torino, Italia.
Rapellino
M
M
Ricci
E
E
Casadio
C
C
Moscato
D
D
Adamo
R
R
Miserendino
L
L
Sansalvadore
F
F
D000230:Adenocarcinoma / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D018288:Carcinoma, Small Cell / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000032:analysis; D006801:Humans; D008175:Lung Neoplasms / Q000032:analysis*; D008970:Molecular Weight; D012907:Smoking
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; C036649:tumor antigen TA-4, human